Companies hope to accelerate fight against cancer
GEDi Cube, an artificial intelligence (AI) company, and Renovaro Biosciences, a pre-clinical biotechnology organization, have revealed an exclusive letter of intent to merge into a single entity. As part of a potential merger, the focus would be on accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases.
"We are rapidly expanding our technologies to include other cancers and diseases," said Craig Rhodes, CEO, GEDi Cube, in a company press release. "I believe that uniting with Renovaro BioSciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”
Reference: AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer. Business Wire. August 9, 2023. Accessed August 10, 2023. https://www.businesswire.com/news/home/20230809952021/en/AI-Company-GEDi-Cube-and-Renovaro-Biosciences-Announce-a-Binding-Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-Cancer
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.